DSpace Community:

Virtual reality-based cognitive assessment tools for mild cognitive impairment screening: comparison with traditional paper-and-pencil-based cognitive assessment tools

Mon, 01 Jun 2026 00:00:00 GMT

Title: Virtual reality-based cognitive assessment tools for mild cognitive impairment screening: comparison with traditional paper-and-pencil-based cognitive assessment tools Authors: Lee, Seungryul; Jang, Sooah; Kim, Eosu; Son, Sang Joon; Kim, Woo Jung; Lee, San; Hong, Chang Hyung; Roh, Hyun Woong; Seok, Jeong-Ho; Jung, Eunjin; 김지혜; Kim, In-young; Oh, Jooyoung; 장수아; 이산 Abstract: Background and Objectives Dementia is becoming increasingly prevalent, highlighting the need for early detection of mild cognitive impairment (MCI), a risk state for dementia. Traditional cognitive assessments often require trained examiners and lack ecological validity. This study examined the diagnostic accuracy of a virtual reality (VR)-based cognitive assessment tool, VARABOM.D, by comparing it with three standard tests: Seoul Neuropsychological Screening Battery (SNSB), Montreal Cognitive Assessment (MoCA), and Mini-Mental State Examination (MMSE).Research Design and Methods Seventy-seven participants, divided into normal (n = 44) and MCI (n = 33) groups based on their Clinical Dementia Rating scores, completed the VARABOM.D program, in addition to SNSB, MoCA, and MMSE. Correlation analyses were performed on the test results, and the specificity, sensitivity, and area under the curve (AUC) of VARABOM.D were compared to those of the other assessments. To monitor for any adverse reactions to the VR environment, the Simulator Sickness Questionnaire (SSQ) was administered both before and after the VR sessions.Results VARABOM.D scores showed significant positive associations with established cognitive assessments. Its AUC values were comparable to those of the MoCA, MMSE, and most SNSB subdomains except for attention, where VARABOM.D demonstrated greater discriminative ability. SSQ scores remained stable across pre- and post-VR sessions in both study groups, underscoring the VR platform's safety and feasibility.Discussion and Implications VARABOM.D demonstrated accuracy comparable to traditional cognitive assessments and even outperformed the attention subdomain of SNSB. Additionally, no adverse reactions were observed in the normal or MCI groups, further emphasizing the safety and stability of VARABOM.D.

Stool DNA-based SDC2 Methylation Test for the Screening of Colorectal Neoplasia in an Asymptomatic, Average-Risk Population

Thu, 01 Jan 2026 00:00:00 GMT

Title: Stool DNA-based SDC2 Methylation Test for the Screening of Colorectal Neoplasia in an Asymptomatic, Average-Risk Population Authors: Il Choi, Hyoung; Cha, Jae Myung; Kim, Young Sang; Cho, Dae Hyeon; Pack, Han Ju; Na, Soo-Young; Kim, Ji Hye; Kim, Hyun Gun; Park, Young-Jin; Kwon, Hye Jung; Kim, Kyeong Ok; Lee, Geon Ho; Lee, Yoo Jin Abstract: Background/Aims: Programmatic screeningfor colorectal cancer (CRC) could maximize the impact of screening in the average-risk population, but the diagnostic performance of a stool DNA-based Syndecan-2 methylation (meSDC2) test has only been reported in case-control studies or high-risk populations. This study examined the performance of a stool DNA-based meSDC2 test for CRC in an average-risk population from a real-world setting. Methods: This retrospective, multicenter study included consecutive asymptomatic, average-risk individuals for CRC who completed a meSDC2 stool test at 18 hospitals. The clinical performance of the meSDC2 stool test, includingthe positive rate, adherence to confirmatory colonoscopy, and the positive predictive value (PPV) for colorectal neoplasia (CRN), was assessed. Results: Over 54 months, 4,910 individuals completed the meSDC2 stool test, with 249 (5.1%) testing positive. The colonoscopy compliance rate after a positive test was 61.0% (n=152). Among 121 individuals with available colonoscopy data, the PPV for any CRN, advanced neoplasia, and CRC were 39.7%, 12.4%, and 2.5%, respectively. Colonoscopy after a positive meSDC2 test ensured a high-quality examination, as reflected by the 100% cecal intubation rate, 97.5% adequate preparation quality, and an average withdrawal time of 11.2 min. Among those with a positive meSDC2 test, a family history of CRC was a significant predictor of any CRN (p=0.029) and advanced neoplasia (p=0.003). Conclusions: A stool DNA-based meSDC2 test in average-risk individuals for CRC revealed a high PPV for any CRN in a real-world setting, highlighting its potential as a screening modality in programmatic CRC screening.

Sex differences of the association between handgrip strength and health-related quality of life among patients with cancer

Mon, 01 Apr 2024 00:00:00 GMT

Title: Sex differences of the association between handgrip strength and health-related quality of life among patients with cancer Authors: Kim, Jihye; Kim, Yujin; Oh, Jae Won; Lee, San Abstract: The purpose of this study is to investigate the association between handgrip strength (HGS) and health-related quality of life (HRQoL), demonstrating HGS as an effective indicator for evaluating HRQoL of patients with cancer. Analyzing 1657 Korean adult cancer patients (644 males, 1013 females) aged >= 20 years from the Korea National Health and Nutrition Examination Survey (2014-2019), HGS was standardized based on body mass index and categorized by sex. HRQoL was assessed using the Euro Quality of Life-5-Dimension 3-Level version (EQ-5D-3L) Index. Lower relative HGS was associated with decreased HRQoL in female patients, while no significant association was found in male patients. The lowest quartile of relative HGS exhibited a 2.5-fold decrease in HRQoL compared to the highest quartile (OR 2.50, 95% CI 1.59-3.95, p < 0.001). Both male and female patients with cancer were affected by age, subjective health perception, and stress recognition regarding HRQoL. This study suggests that HGS may be associated with the HRQoL of female patients with cancer, emphasizing that the HGS measurement can be effectively utilized as a pivotal tool for evaluating HRQoL in female patients with cancer.

Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgE_Trap-Fc protein in subjects with Atopy: Results from the First-in-Human study

Fri, 01 Mar 2024 00:00:00 GMT

Title: Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgE_Trap-Fc protein in subjects with Atopy: Results from the First-in-Human study Authors: Ye, Young-Min; Park, Jung-Won; Kim, Sae-Hoon; Cho, You Sook; Lee, Sook Young; Lee, Sae Young; Sim, Sujin; Song, Eunji; Kim, Bomin; Lee, Jieon; Kim, Su Kyung; Jang, Myoung Ho; Park, Hae-Sim Abstract: Background: YH35324, a long-acting IgETrap-Fc fusion protein, is a novel therapeutic agent for immunoglobulin E (IgE)-mediated allergic diseases. This randomized, double-blind, placebo/active-controlled, single ascending dose Phase 1 study assessed the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of YH35324 in subjects with atopy. Methods: Eligible subjects were healthy subjects or atopic adults with mild allergic rhinitis, atopic dermatitis, food allergy, or urticaria, and a serum total IgE level of 30-700 IU/mL (Part A) or > 700 IU/mL (Part B). In Part A, 35 subjects in 5 cohorts received YH35324 (0.3, 1, 3, 6, and 9 mg/kg), 8 received omalizumab (300 mg), and 9 received placebo. In Part B, 8 subjects received YH35324 and 8 received omalizumab. Results: Twenty subjects (38.5 %) in Part A (YH35324: 37.1 %, omalizumab: 50.0 %, placebo: 33.3 %) and 10 subjects (62.5 %) in Part B (YH35324: 100 %; omalizumab: 25.0 %) experienced treatment-emergent adverse events (TEAEs). TEAEs were mostly grade 1/2; no serious AEs, AE-related treatment discontinuation, or anaphylaxis were reported. YH35324 exhibited dose-proportional increase in C-max and AUC(last) over the dose range of 0.3-9 mg/kg. YH35324 rapidly suppressed serum-free IgE levels to a significant extent (< 25 and < 82.8 ng/mL, both P < 0.05) and with longer duration than omalizumab. Conclusion: This study showed that YH35324 has a favorable safety profile and is effective in reducing serum-free IgE levels in subjects with atopic conditions.

DSpace Community:

Virtual reality-based cognitive assessment tools for mild cognitive impairment screening: comparison with traditional paper-and-pencil-based cognitive assessment tools

Stool DNA-based SDC2 Methylation Test for the Screening of Colorectal Neoplasia in an Asymptomatic, Average-Risk Population

Sex differences of the association between handgrip strength and health-related quality of life among patients with cancer

Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgETrap-Fc protein in subjects with Atopy: Results from the First-in-Human study

Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgE_Trap-Fc protein in subjects with Atopy: Results from the First-in-Human study